-
1.发明公开
公开(公告)号：EP2131200A1
公开(公告)日：2009-12-09
申请号：EP08157595.3
申请日：2008-06-04
发明人： Struck, Joachim , Bakker, S.J.L.
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/585 , G01N2800/245
摘要： Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction of risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.
摘要翻译： 本发明的主题是器官移植后移植物衰竭和/或死亡率的生物标志物。 发现降钙素原是预测接受器官移植的受试者的移植物衰竭和/或死亡率的风险分层和对该受试者的监测和治疗指导的有用标志物。
-
2.发明公开Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes 审中-公开Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen
公开(公告)号：EP2101178A1
公开(公告)日：2009-09-16
申请号：EP08152651.9
申请日：2008-03-12
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/324
摘要： Subject of the present invention are assays and in vitro methods for determining a prognosis for a patient having an acute coronary syndrome, whereby the level of procalcitonin or fragments thereof is measured in a sample obtained from said patient. Said level of procalcitonin or fragments thereof may then be correlated to a predisposition to an adverse outcome of said acute coronary syndrome.
摘要翻译： 本发明的主题是用于确定具有急性冠状动脉综合征的患者的预后的测定和体外方法，由此在从所述患者获得的样品中测量降钙素原或其片段的水平。 所述降钙素原或其片段的水平可以与所述急性冠状动脉综合征的不良结果的倾向相关。
-
3.发明公开Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events 审中-公开Pro-Endothelin-1-Spiegelfürdie Risikobestimmung von tachyarrhthmischen Ereignissen
公开(公告)号：EP2107377A1
公开(公告)日：2009-10-07
申请号：EP08154109.6
申请日：2008-04-04
CPC分类号： G01N33/74 , G01N33/6893 , G01N2333/5754 , G01N2800/326
摘要： The invention relates to in vitro methods for prognosis and risk-stratification for a patient having a cardiac disease as heart failure. The invention further relates to the use of such a method.
摘要翻译： 本发明涉及具有心脏病作为心力衰竭的患者的预后和风险分层的体外方法。 本发明还涉及这种方法的使用。
-
公开(公告)号：EP2020603A1
公开(公告)日：2009-02-04
申请号：EP07015271.5
申请日：2007-08-03
发明人： Bergmann, Andreas , Struck, Joachim , Morgenthaler, Nils G. , Papassotiriou, Jana , Blankenberg, Stefan, Prof. Dr. , Lackner, Karl, Prof. Dr. , Rupprecht, Hans, Prof. Dr. , Bickel, Christoph, Prof. Dr.
IPC分类号： G01N33/74
CPC分类号： G01N33/74 , G01N33/53 , G01N2333/585 , G01N2800/323 , G01N2800/324 , G01N2800/50 , G01N2800/54
摘要： In vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with the personal cardiac risk, and the patients are allotted to one of said risk groups on the basis of their individual PCT concentrations
摘要翻译： 用于稳定动脉硬化，特别是冠状动脉疾病稳定的患者的风险分层的体外方法，其中使用高度敏感的PCT测定在这些患者的循环中测定降钙素原的浓度，并且其中在典型的PCT浓度范围内 定义健康个体临界值的正常范围，其根据个人心脏风险区分具有稳定动脉硬化的个体患者群体，并且根据其各自的PCT浓度将患者分配到所述风险组之一
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
